Clinical and laboratory characteristics of new coronaviral infection (COVID-19) in children

Abstract

The review analyzed the problem of patients with kidney disease and approaches to vaccination of this group during the COVID-19 pandemic caused by the virus SARS-CoV-2. Patients with comorbid diseases are a vulnerable group for infection with a severe course and an unfavorable outcome, which is also confirmed in this pandemic.

The aim – analysis of the available literature data on vaccination of patients with kidney disease and determination of the role of vaccine prophylaxis against coronavirnus infection. The analysis was carried out methodologically, using a systematic approach based on the material of various databases of biomedical scientific information, mainly for 2020–2021.

Results. The analysis of the category of patients with kidney diseases was given. The possible role of disturbances in the morphofunctional state and defense mechanisms of the kidneys in coronavirus infection has been shown. Methods and approaches to vaccination of patients of this group are reflected.

Keywords:chronic pathology; kidney diseases; vaccination; vaccines; postvaccinal immunity; SARS-CoV-2; COVID-19

Funding. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Contribution. Concept and design of the lecture – Kostinov M.P.; the collection and processing of the material – Khasanova А.А., Cherdantsev А.Р.; writing a text – Khasanova А.А., Soloveva I.L., Cherdantsev А.Р.; editing – Kostinov M.P., Soloveva I.L.

For citation: Khasanova А.А., Kostinov М.Р., Soloveva I.L., Cherdantsev A.P. Vaccination against COVID-19 in patients with kidney diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (2): 91–6. DOI: https://doi.org/10.33029/2305-3496-2022-11-2-91-96

References

1.Soliman N.A. COVID-19 infection and the kidneys: learning the lesson. Infect Public Health. 2021; 14 (7): 922–6. DOI: https://doi.org/10.1016/j.jiph.2021.05.010

2. Moledina D.G., Simonov M., Yamamoto Y., et al. The association of COVID-19 with acute kidney injury independent of severity of illness: a multicenter cohort study. Am J Kidney Dis. 2021; 77 (4): 490–9.e1. DOI: https://doi.org/10.1053/j.ajkd.2020.12.007

3. Oyelade T., Alqahtani J., Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. Trop Med Infect Dis. 2020; 5 (2): 80. DOI: https://doi.org/10.3390/tropicalmed5020080

4. Guan W.-J., Liang W.-H., Zhao Y., Liang H.-R., Chen Z.-S., Li Y.-M., et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55 (5): 2000547. DOI: https://doi.org/10.1183/13993003.00547-2020

5. Hu L., Chen S., Fu Y., Gao Z., Long H., Wang J.-M., et al. Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. Clin Infect Dis. 2020. DOI: https://doi.org/10.1101/2020.03.25.20037721

6. Arentz M., Yim E., Klaff L., et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020; 323 (16): 1612–4. DOI: https://doi.org/10.1001/jama.2020.4326

7. Wang X., Fang X., Cai Z., Wu X., Gao X., Min J., et al. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis. Research (Wash DC). 2020. DOI: https://doi.org/10.34133/2020/2402961

8. Henry B.M., Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020; 52 (6): 1193–4. DOI: https://doi.org/10.1007/s11255-020-02451-9

9. Pei G., Zhang Z., Peng J., Liu L., Zhang C., Yu C., et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. 2020; 31 (6): 1157–65. DOI: https://doi.org/10.1681/ASN.2020030276

10.Krueger K.M., Ison M.G., Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020; 75 (3): 417–25. DOI: https://doi.org/10.1053/j.ajkd.2019.06.014

11.Waldman M., Soler M.J., García-Carro C., et al. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int. 2021; 99 (1): 227–37. DOI: https://doi.org/10.1016/j.kint.2020.10.032

12. Wang D., Hu B., Hu C., Zhu F., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–9. DOI: https://doi.org/10.1001/jama.2020.1585

13. Akalin E., Azzi Y., Bartash R., et al. COVID-19 and kidney transplantation. N Engl J Med. 2020; 382 (25): 2475−7. DOI: https://doi.org/10.1056/NEJMc2011117

14. Fernandez-Ruiz M., Andres A., Loinaz C., et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020; 20 (7): 1849−58. DOI: https://doi.org/10.1111/ajt.15929

15. Alberici F.D., Delbarba E., Manenti C., et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020; 97 (6): 1083−8. DOI: https://doi.org/10.1016/j.kint.2020.04.002

16. Banerjee D.P., Shah S., Ster I.C., et al. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020; 97 (6): 1076−82. DOI: https://doi.org/10.1016/j.kint.2020.03.018

17. Shahid Z., Kalayanamitra R., McClafferty B., et al. COVID-19 and older adults: what we know. J Am Geriatr Soc. 2020; 68 (5): 926–9. DOI: https://doi.org/10.1111/jgs.16472

18. Soliman N.A. COVID-19 infection and the kidneys: learning the lesson. J Infect Public Health. 2021; 14 (7): 922–6. DOI: https://doi.org/10.1016/j.jiph.2021.05.010

19. Kostinov M.P., Svitich O.A., Markelova E.V. Potential COVID-19 immunoprophylaxis in high-risk groups: Manual for doctors. Moscow: MDV, 2020: 64 p. (in Russian)

20. Kostinov M.P. Immunopathogenic properties of SARS-CoV-2 as a basis for the choice of pathogenetic therapy. Immunologiya [Immunology]. 2020; 41 (1): 83–91. DOI: https://doi.org/10.33029/0206-4952-2020-41-1-83-91 (in Russian)

21. Kostinov M.P. Fundamentals of immunorehabilitation in new coronavirus infection (COVID-19): Manual for doctors. Moscow: MDV, 2020: 112 p. (in Russian)

22. Gibertoni D., Reno C., Rucci P., et al. COVID-19 incidence and mortality in non-dialysis chronic kidney disease patients. PLoS One. 2021; 16 (7). DOI: https://doi.org/10.1371/journal.pone.0254525

23. Kann M., Benzing T. Update 2021: COVID-19 aus Sicht der Nephrologie [Update 2021: COVID-19 from the perspective of nephrology]. Dtsch Med Wochenschr. 2021; 146 (13–14): 915–7. DOI: https://doi.org/10.1055/a-1449-5068

24.Khehra N., Padda I., Jaferi U., et al. (BNT162b2) vaccine: the journey from preclinical research to clinical trials and authorization. AAPS PharmSciTech. 2021; 7 (22): 172. DOI: https://doi.org/10.1208/s12249-021-02058-y

25. Kostinov M.P., Kharseeva G.G., Tyukavkina S.Yu. Vaccination of people with chronic pathology (material for preparing the lecture). Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2021; 10 (2): 99–108. DOI: https://doi.org/10.33029/2305-3496-2021-10-2-99-108 (in Russian)

26.Kostinov M.P., Maleev V.V. Hib-infection: issues of vaccine prevention. Moscow: Meditsina dlya vsekh, 1998: 78 p. (in Russian)

27.Kostinov M.P., Chuchalin A.G. (eds). Guidelines for clinical immunology in respiratory medicine. 2nd ed. Moscow: MDV, 2018: 304 p. (in Russian)

28. Goupil R., Benlarbi M., Beaubien-Souligny W., et al. Réseau rénal québécois (quebec renal network) COVID-19 study investigators. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. CMAJ. 2021; 193 (22): 793–800. DOI: https://doi.org/10.1503/cmaj.210673

29. Korth J., Jahn M., Dorsch O., et al. Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech). Viruses. 2021; 13 (5): 756. DOI: https://doi.org/10.3390/v13050756

30. Sánchez-Álvarez E., Quiroga B., de Sequera P. Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines. Nefrologia (Engl. Ed.). 2021; 41 (4): 412–6. DOI: https://doi.org/10.1016/j.nefro.2020.12.002

31. Chavarot N., Ouedrani A., Marion O., et al. Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with Belatacept. Transplantation. 2021; 105 (9): e94–5. DOI: https://doi.org/10.1097/TP.0000000000003784

32. Walsh E.E., Frenck R.W., Falsey A.R., et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020; 383 (25): 2439–50. DOI: https://doi.org/10.1056/nejmoa2027906

33. Dagan N., Barda N., Kepten E., et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384 (15): 1412–23. DOI: https://doi.org/10.1056/NEJMoa2101765

34. Stumpf J., Siepmann T., Lindner T., et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021; 9. DOI: https://doi.org/10.1016/j.lanepe.2021.100178

35. Kostinov M.P. (ed.). Immunocorrection in pediatrics: A practical guide for doctors. Moscow: Meditsina dlya vsekh, 1997: 111 p. (in Russian)

36. Solov’ova I.L. Kostinov M.P., Kusel’man A.I. Features of vaccination of children with altered premorbid background against hepatitis B, measles, mumps. Ulyanovsk: UlGU, 2006: 296 p. (in Russian)

37. Kostinov M.P., Zverev V.V. (eds). Vaccination against hepatitis B, influenza and rubella in adult patients with chronic diseases: Manual. Moscow: MDV, 2009: 196 p. (in Russian)

38. Kostinov M.P. (ed.). Vaccination of children with kidney diseases. A practical guide for doctors. Moscow, MDV, 2012: 95 p. (in Russian)

39. Broseta J.J., Rodríguez-Espinosa D., Rodríguez N., et al. Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis. 2021; 78 (4): 571–81. DOI: https://doi.org/10.1053/j.ajkd.2021.06.002

40. Lesny P., Anderson M., Cloherty G., et al. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. J Nephrol. 2021; 34: 975–83. DOI: https://doi.org/10.1007/s40620-021-01076-0

41. Rincon-Arevalo H., Choi M., Stefanski A.L., et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021; 6 (60). DOI: https://doi.org/10.1126/sciimmunol.abj1031

42. Yanay N.B., Freiman S., Shapira M., et al. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int. 2021; 99 (6): 1496–8. DOI: https://doi.org/10.1016/j.kint.2021.04.006

43. Stumpf J., Siepmann T., Lindner T., et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021. DOI: https://doi.org/10.1016/j.lanepe.2021. 100178

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»